|
US2006008415A1
|
|
Stable liquid and lyophilized formulation of proteins
|
|
WO2005123780A2
|
|
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US2005025763A1
|
|
Therapeutic use of anti-CS1 antibodies
|
|
WO2004101511A2
|
|
Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
|
|
CN1798767A
|
|
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US2005019323A1
|
|
Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
|
|
WO2005014653A2
|
|
Humanized chicken antibodies
|
|
EP1608684A2
|
|
Amphiregulin antibodies and their use to treat cancer and psoriasis
|
|
US2004141983A1
|
|
Compositions against cancer antigen LIV-1 and uses thereof
|
|
WO2004067564A2
|
|
Compositions against cancer antigen liv-1 and uses thereof
|
|
AU2003299747A1
|
|
Tumor killing/tumor regression using cxcr4 antagonists
|
|
AU2003298786A1
|
|
Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
|
|
AU2003287564A1
|
|
Methods of detecting colorectal cancer
|
|
WO2004039337A2
|
|
Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
|
|
WO2004035752A2
|
|
ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
|
|
US2004115814A1
|
|
Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
|
|
US2003229208A1
|
|
Humanized immunoglobulins
|
|
CA2478683A1
|
|
Antibodies against cancer antigen tmeff2 and uses thereof
|
|
AU2002357734A1
|
|
Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
|
|
WO03042661A2
|
|
Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
|
